Finding the Right Patient for Lutetium-177 PSMA Treatment
November 04, 2024
Videos
PEER-TO-PEER CLINICAL CONVERSATIONS
ctDNA Fraction Predicts Response to Lutetium PSMA in TheraP Trial for mCRPC
Edmond Kwan, MBBS, PhD
Edmond Kwan discusses his latest research on circulating tumor DNA as a predictive marker for response to Lutetium PSMA-617 versus cabazitaxel. The Phase II TheraP trial compared these treatments in patients with advanced metastatic castration-resistant prostate cancer, utilizing dual imaging selection.
Finding the Right Patient for Lutetium-177 PSMA Treatment
Kara Cossis, PA-C, MPH
Phillip Koo converses with Kara Cossis about the critical aspect of patient selection for (PLUVICTO®) Lutetium Lu 177 vipivotide tetraxetan treatment. Ms. Cossis outlines the criteria for identifying suitable candidates, emphasizing the role of castrate-resistant metastatic prostate cancer, disease burden, and eligibility based on scans.
COBRA Trial Shows Promise for 64Cu-SAR-bisPSMA PET in Biochemical Recurrence
Neal Shore, MD, FACS
Phillip Koo and Neal Shore discuss the COBRA trial, which investigates the use of 64Cu-SAR-bisPSMA PET imaging in prostate cancer patients with biochemical recurrence (BCR).
Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu PSMA Therapy: Comparison to Quantitative SUVmean and Patient Outcomes
Mina Swiha, MD, Ph.D.
Mina Swiha presents a new visually calculated SUVmean (HIT Score) on screening PSMA PET/CT to predict treatment response to 177Lu PSMA therapy. The HIT Score, combining tumor heterogeneity and intensity, proved comparable to quantitative SUVmean in predicting treatment outcomes for metastatic castrate-resistant prostate cancer. Further validation studies are needed to confirm its clinical utility.
Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes - Beyond the Abstract
Mina Swiha, MD, Ph.D.
177Lu-PSMA therapy is an effective treatment in patients with metastatic castration-resistant prostate cancer. SUVmean is a valuable screening biomarker to assess the suitability for 177Lu-PSMA therapy but requires quantitative software.
